Skip to main content

Table 4 Characteristics of the patients who used glucocorticoids (GCs) and presented adverse drug reactions (ADRs)

From: Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort

Variable ADRs of glucocorticoid (N = 339)
Yes n (151) No n (188) ρ*
Sex (%)
 Female 122 (48.2) 131 (51.8) 0.019
 Male 29 (33.7) 57 (66.3)  
Age
  ≤ 16 135 (56.3) 105 (43.7) < 0.001
  > 16 years 16 (16.2) 83 (83.8)  
Type of glucocorticoid
 Methylprednisolone 3 (12.5) 21 (87.5) < 0,001
 Prednisone 71 (100) 0 (0.0)  
 Prednisone / Methylprednisolone** 77 (31.6) 167 (68.4)  
Dose of prednisone (mg/kg/day) ***
  ≥ 0,5 91 (58.1) 65 (41.9) < 0.001
  < 0,5 57 (35.8) 102 (64.2)  
Disease
 JIA 18 (12.8) 123 (87.2) < 0.001
 JSLE 120 (82.8) 25 (17.2)  
 JDM 13 (24.5) 40 (75.5)  
  1. N - number of patients treated with GCs, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis
  2. * Chi Pearson square or Fisher’s exact P < 0.05
  3. ** Prednisone (oral) / Methyprednisolone (pulse therapy) indicates patients treated with GCs and who presented ADRs during the use of combined oral and pulse therapy. Three patients with ADRs and 21 patients in the group without ADRs did not use GCs orally but used pulse therapy only
  4. *** The dose of 30 mg/kg/dose of pulse therapy was not considered in the calculation